U.S. Markets close in 4 hrs 52 mins

Ortho Regenerative Technologies Inc. (ORTIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.58460.0000 (0.00%)
As of 3:21PM EST. Market open.

Ortho Regenerative Technologies Inc.

16667 Hymus Boulevard
Kirkland, QC H9H 4R9
514 782 0951

IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Claude LeDucPres, CEO & DirectorN/AN/A1956
Mr. Luc Mainville M.B.A., M.B.ASr. VP & CFON/AN/A1964
Prof. Michael BuschmannChief Scientific Officer & DirectorN/AN/A1962
Frederic DumaisDirector of Communications & Investor RelationsN/AN/AN/A
Mr. Guy Paul AllardVP of Legal Affairs & Corp. Sec.N/AN/AN/A
Benedek SimoControllerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a formulation for rotator cuff repair; and Ortho-M, a biopolymer for bioactive meniscus repair. It also develops Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.

Corporate Governance

Ortho Regenerative Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.